ClinicalTrials.gg
RecruitingNCT05293197SONOKIDUpdated May 6, 2026

Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

A Phase 1 interventional study of SonoCloud® (9 transducers) in Malignant Brain Tumor, Malignant Glioma and Embryonal Tumor, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Brain Neoplasms by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 5 under way, none of them phase 3. Brain Neoplasms · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
9th of 11
24 · median 60
Started
2023
with 1 other
Phase 1
Only one
of the 15
Registered
12th of 15
by date

Among the 15 studies in Brain Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 1, and was the 12th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

5 of the 15 studies in Brain Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Brain Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Purpose : the aim of this study is to assess the feasibility and safety of ultrasound-induced opening of the blood-brain barrier (BBB) with the SonoCloud-9 implantable ultrasound device in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor treated with carboplatin.

Study hypothesis : the blood-brain barrier can be transiently and safely opened with pulsed low intensity ultrasound immediately prior to intravenously delivered chemotherapy. The opening of the BBB with the SonoCloud-9 system will increase the tumor exposure to carboplatin and increase progression-free and overall survival in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor.

Read the detailed description

Malignant brain tumors are the first cause of death by cancer in children and adolescents. The dismal prognosis of malignant brain tumors is partially due to the existence of the blood brain barrier (BBB), a physiological barrier that limits the penetration of almost all molecules from the blood stream to the brain, including antineoplastic drugs.

It has been shown that the application of low intensity ultrasound on the brain in association with intravenous microbubbles leads to transient and safe opening of the BBB. Many preclinical studies have demonstrated that ultrasound-induced opening of the BBB increases the distribution of therapeutic molecules into the brain and allows tumor control and increases survival in animal models (mice, rabbits, pigs, primates).

An innovative implantable ultrasound system, the SonoCloud device, has been developed in order to repeatedly open the BBB in synchronization with chemotherapy protocols.

This intracranial and subcutaneous device is not visible and MRI compatible and allows repeatable and ambulatory treatments. Moreover, such a device allows the delivery of low intensity ultrasound in a controlled and reproductible manner.

A phase I/IIa trial has confirmed the feasibility and safety of this technique in adult patients treated for recurrent glioblastoma with carboplatin-based chemotherapy.

This study will assess the feasibility and safety of ultrasound-induced opening of the BBB with the SonoCloud device in pediatric patients treated with carboplatin chemotherapy for a recurrent supra-tentorial malignant brain tumor. The study will determine the maximum tolerated ultrasound acoustic pressure that can be used for BBB opening and the safety of the activation of 3, then 9 transducers with the SonoCloud-9® device. Patients will follow 6 months cycles of treatment. If the treatment is well tolerated, patients will be able to be treated for 6 more cycles.

The magnitude and intensity of the BBB opening, its clinical (overall survival) and radiological (progression-free survival) efficacy will be assessed as secondary endpoints. Safety of the ultrasound contrast agent SonoVue will also be evaluated in this indication in the pediatric population.

An ancillary study will assess circulating tumor DNA (ctDNA) concentrations in patients with recurrence of a supra-tentorial malignant brain tumor, at diagnosis and during repeated opening of the BBB. The study will assess the correlation between ctDNA concentrations and tumor evolution.

03

Conditions studied

  • Malignant Brain Tumor
  • Malignant Glioma
  • Embryonal Tumor

Keywords

  • Low intensity pulsed ultrasound (LIPU)
  • Therapeutic ultrasound
  • Blood-brain barrier (BBB)
  • Malignant brain tumor
  • Brain cancer
  • Carboplatin
  • Children
  • Adolescents
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient aged ≥ 5 years old and \< 18 years old
  • patient able to receive sonications and perform MRI studies without sedation
  • diagnosis of supra-tentorial primary malignant brain tumor (e.g. malignant glioma, embryonal tumor including ATRT, ependymoma)
  • recurrence or progression of brain tumor after at least a of standard treatment (multifocal tumors and disease allowed)
  • indication of treatment with carboplatin, validated in multidisciplinary meeting
  • performance scale index (patients ≥ 16 years old) or Lansky performance status (patients \< 16 years old) > 50% (a patient with a performance status score altered by a motor deficit due to tumor infiltration will be allowed to be included)
  • no threat of brain herniation or uncontrolled intracranial hypertension
  • treatment ≤ 1mg/kg/day
  • neutrophils > 1.5 x 109/L
  • > 100 x 109/L
  • total \< 1.5x , et ALT \< 2.5x upper limit of normal
  • serum creatinin \< 1.5x upper limit of normal for the age or creatinine clairance >70mL/min/1.73m2 (EDTA method or 24h urine)
  • coagulation parameters in the normal limits for age (fibrinogen, and activated clotting time)
  • no grade 2 or more toxicity depending on the v5.0 criteria
  • no healed wound on the scalp
  • covered by health insurance
  • for patients of chilbearing age (15-17 years old) : a negative pregnancy test and an efficient method of
  • written consent signed by the patient (if possible) and his parents or legal representatives.

Exclusion criteria

Exclusion Criteria:

  • weight \<15kg
  • significant intra-tumoral bleeding (hematoma) or ipsilateral subdural effusion
  • antineoplastic treatment other than carboplatin taken at the same time or stopped since less than:

    • 6 weeks for nitrosoureas
    • 1 month for temozolomide
    • 1 month for bevacizumab
    • 5 half-lives for tyrosin kinase inhibitors
    • 3 weeks for any other chemotherapy

for the first sonication session

  • radiotherapy during the last 6 weeks
  • any other cancer treated during the last 5 years
  • any other uncontrolled disease or active infection
  • any other co-morbidity that could compromise participation to the study (in the judgement of the clinical investigator)
  • any anatomical particularity (skull thickness, thin skin) that could compromise a safe implantation of the device and/or compromise the quality of the treatment (in the judgement of the clinical investigator)
  • implanted defibrillator/pacemaker, neurostimulator, cochlear implant, intracerebral ferromagnetic vascular clip
  • any to general anesthesia
  • any contraindication to MRI or known allergy to gadolinium or other MRI contrast agent/
  • any contraindication to ultrasound contrast agent:

    • allergy to the active substance or any
    • acute coronary syndrome or uncontrolled ischemic heart disease
    • chronic heart failure or history of acute heart failure or heart failure grade III or IV
    • treatment with dobutamine
    • severe pulmonary arterial hypertension
    • uncontrolled systemic hypertension
    • respiratory distress syndrome
  • carboplartin
  • treatment with phenytoin or fosphenytoin
  • earlier vaccination with attenuated alive vaccine
  • diminished auditory acuity ≥ grade 3 on classification
  • history of thermoregulation disorder
  • impossibility of a rigorous medical follow-up due to geographic, social or mental reasons
  • pregnant and lactating women
  • contemporaneous treatment by anticoagulant or aggregation inhibiting drugs
  • contemporaneous treatment possibly toxic for the central nervous system. The following treatments are excluded if taken less than 5 half-lives before the ultrasound session (unknown toxicity in case of BBB disruption) :

    • benzodiazepine (or any sedative or hypnotique drug)
    • antihistamine
    • proconvulsant drugs
    • butyrophenone, phenothiazine, or any "conventional" antipsychotic drug
    • barbiturate
    • MAO inhibitor
    • anticholinergic
    • anticoagulant
  • any contemporaneous treatment that, in the judgement of the clinical investigator, could induce brain toxicity after BBB disruption
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    SonoCloud®

    SonoCloud® : dose escalation 6 cycles of sonication

    Device: SonoCloud® (9 transducers)

Interventions

  • DeviceSonoCloud® (9 transducers)

    SonoCloud®, sonication: dose escalation 6 cycles of sonication

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity directly linked to US emissions by the SonoCloud-9® (3 transducers)

    Clinical evaluation (neurological deficit, intracranial hypertension, epilepsy) during acoustic pressure dose escalation, after each sonication (48h)

    Time frame: Monthly up to 12 months

  2. Dose limiting toxicity directly linked to US emissions by the SonoCloud-9®(3 transducers)

    Radiological evaluation (hemorrage, ischemia, brain swelling) during acoustic pressure dose escalation, after each sonication

    Time frame: Monthly up to 12 months

Secondary outcomes

  1. BBB opening intensity with the SonoCloud® device

    Grading of BBB disruption using the scale previously described (Carpentier et al 2016), after each sonication

    Time frame: Monthly, up to 12 months

  2. Clinical efficacy of BBB disruption by the SonoCloud® device in association with systemic chemotherapy

    Overall Survival (OS)

    Time frame: Month 3

  3. Clinical efficacy of BBB disruption by the SonoCloud® device in association with systemic chemotherapy

    Overall Survival (OS)

    Time frame: Month 6

  4. Radiological efficacy of BBB disruption by the SonoCloud® device in association with systemic chemotherapy

    Progression Free Survival (PFS) using RANO Criteria

    Time frame: Month 3

  5. Radiological efficacy of BBB disruption by the SonoCloud® device in association with systemic chemotherapy

    Progression Free Survival (PFS) using RANO Criteria

    Time frame: Month 6

  6. Allergic adverse events related to ultrasound contrast agent SonoVue®

    Allergic reactions (cutaneous eruption, oedema, respiratory failure) in relation to the use of the ultrasound contrast agent SonoVue® for BBB disruption in the pediatric population, during and after each sonication

    Time frame: Monthly, up to 12 months

  7. Cardiac adverse events related to ultrasound contrast agent SonoVue®

    Cardiac reactions (thoracic pain, cardiac failure, EKG modification) in relation with the use of the ultrasound contrast agent SonoVue® for BBB disruption in the pediatric population, during and after each sonication

    Time frame: Monthly, up to 12 months

  8. Feasibility of the BBB disruption technique

    Complications associated with the implantation of the SonoCloud® device : acute pain evaluation using VAS (Visual Analogue Scale) for patients \>\_ 7 years old or using behavioral pain scale EVENDOL for patients \<7 years old, immediately after implantation

    Time frame: Monthly, up to 12 months

  9. Feasibility of the BBB disruption technique

    Complications associated with the implantation of the SonoCloud® device : acute pain evaluation using VAS (Visual Analogue Scale) for patients \>\_ 7 years old or using behavioral pain scale EVENDOL for patients \<7 years old, at day 1 after implantation

    Time frame: Monthly, up to 12 months

  10. Feasibility of the BBB disruption technique

    Complications associated with the implantation of the SonoCloud® device : chronic pain evaluation using VAS (Visual Analogue Scale) for patients \>\_7 years old or using behavioral pain scale EVENDOL for patients \<7 years old, monthly, before each new cycle of treatment

    Time frame: Monthly, up to 12 months

  11. Feasibility of the BBB disruption technique

    Complications associated with the implantation of the SonoCloud® device using radiological examination : device position and post-operative complication (hematoma), one day after implantation

    Time frame: Day 1 after implantation

  12. Feasibility of the BBB disruption procedure

    Assessment of complications associated with the sonications : pain evaluation using VAS (Visual Analogue Scale) for patients \>\_ 7 years old or using behavioral pain scale EVENDOL for patients \<7 years old at needle connexion

    Time frame: Monthly, up to 12 months

  13. Feasibility of the BBB disruption procedure

    Complications associated with the implantation of the SonoCloud® device : pain evaluation using VAS (Visual Analogue Scale) for patients \>\_ 7 years old or using behavioral pain scale EVENDOL for patients \<7 years old, during sonication

    Time frame: Monthly, up to 12 months

  14. Skin complications relation to the BBB disruption procedure

    Assessment of skin complications associated with sonications : eschar and/or infection, before each cycle of treatment

    Time frame: Monthly, up to 12 months

  15. Feasibility of the BBB disruption procedure

    Process evaluated by the surgeon: number of tests necessary for needle connexion to the device, at each sonication

    Time frame: Monthly, up to 12 months

  16. Feasibility of the BBB disruption procedure

    Process evaluated by the surgeon : duration from needle connexion to the end of sonication, at each sonication

    Time frame: Monthly, up to 12 months

  17. Feasibility of the BBB disruption procedure

    Process evaluated by the surgeon : duration for device implantation

    Time frame: During surgery

  18. Biodisponibility of the SonoCloud-9® device

    Histological analysis of tissue around the device : thickness, inflammation, biocompatibility, at explantation

    Time frame: 12 months

  19. Assessment of SonoCLOUD- 9® device resistance

    Physical analysis of the device, at explantation

    Time frame: 12 months

  20. DNA and tumor cells concentrations in blood and cerebrospinal fluid

    Evaluation of the effect of BBB disruption with the SonoCloud-9® device on the circulation of tumoral components in the blood flow, at each cycle of treatment

    Time frame: Monthly, up to 12 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon JY, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre JY, Idbaih A. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016 Jun 15;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086. PubMed 27306666 ↗
  • Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, Andre A, Lafon C, Chapelon JY, Delattre JY, Carpentier A. Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19. PubMed 30890548 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Oct 2026, 43 months after the start.

Of 177 non-industry phase 1 interventional studies under Brain Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 43 months is below that.

Counting every sponsor, half of 205 studies reached it within 54 months; a quarter within 36 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2022
First posted
Mar 24, 2022
StartActual
Feb 6, 2023
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05293197
Collaborators
CarThera, Gustave Roussy, Cancer Campus, Grand Paris, Institut Curie, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Mar 24, 2022
Start date
Feb 6, 2023
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
May 6, 2026

Study contacts

Kevin BECCARIA, MD, PhD
Contact
kevin.beccaria@aphp.fr
+33 1 71 39 65 92
Nelly BRIAND, MD, PhD
Contact
nelly.briand@aphp.fr
+33 1 44 38 18 62
Kevin BECCARIA, MD, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion